AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LIQUID FORM (VERSIONS) Russian patent published in 2021 - IPC C12N15/86 A61K39/215 A61P31/14 C12N7/00 

FIELD: medicine.

SUBSTANCE: invention relates to biotechnology, immunology and virology. A means for inducing specific immunity against the SARS-CoV-2 severe acute respiratory syndrome virus in liquid form is described, containing as the only active component an expression vector based on the genome of the recombinant human adenovirus strain of the 26th serotype, in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an inserted expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. In another embodiment, the agent contains, as the only active component, a genome-based expression vector recombinant human adenovirus strain of the 5th serotype, in which the E1 and E3 regions are deleted, with an inserted expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. In another embodiment, the agent contains as the only active component is an expression vector based on the genome of the recombinant simian adenovirus strain of the 25th serotype, in which the E1 and E3 regions are deleted, with built-in expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3. In this case, in the particular case of its implementation, the buffer solution of the means for liquid form contains, mass. %: tris from 0.1831 to 0.3432, sodium chloride from 0.3313 to 0.6212, sucrose from 3.7821 to 7.0915, magnesium chloride hexahydrate from 0.0154 to 0.0289, EDTA from 0.0029 to 0.0054, polysorbate-80 from 0.0378 to 0.0709, ethanol 95% from 0.0004 to 0.0007, water is the rest. The product is intended for intranasal or intramuscular administration. Also, the agent can be administered jointly and simultaneously intranasally and intramuscularly.

EFFECT: proposed agent can be used for the prevention of diseases caused by the severe acute respiratory syndrome SARS-CoV-2 virus, providing an effective induction of an immune response against the SARS-CoV-2 virus in the general population.

8 cl, 4 dwg, 5 tbl, 12 dwg